Trials / Unknown
UnknownNCT03758105
Transcranial Direct Current Stimulation (tDCS) Cost-utility-analysis in Medical Care on Depressive Episode With One Drug Therapy Failure.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 214 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the transcranial direct current stimulation (tDCS) cost-utility in the depression therapy. This is a 3 years medico-economics study with 1 year follow-up period involving patients with 1 or 2 depression treatment(s) failed. Eligible subject will be randomized in 2 groups, usual care with tDCS cure (arm A) or only usual care (arm B).
Detailed description
Transcranial direct current stimulation is a non-invasive brain neuromodulation technique. tDCS can be a new therapy in depression. This study focuses on tDCS cost-utility-analysis. Each patient is following during 12 months. Patients are randomized in 2 arms. Arm A usual care with tDCS cure or arm B usual care without tDCS. Patient in arm A get a initial tDCS cure one week after randomization. If these patients are answering to the treatment, they can have a new cure in case of relapse. This new cure can start from the second month following initial treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | tDCS associated with usual care | A tDCS cure will be given to the group "tDCS", one week after their randomization. This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current. Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks. |
| OTHER | Usual care | Medication and psychotherapy as prescribed in usual care |
Timeline
- Start date
- 2019-02-04
- Primary completion
- 2023-11-11
- Completion
- 2023-11-11
- First posted
- 2018-11-29
- Last updated
- 2023-02-27
Locations
12 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03758105. Inclusion in this directory is not an endorsement.